2 Information about palbociclib

Marketing authorisation indication

2.1 Palbociclib (Ibrance, Pfizer) is indicated 'for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone agonist'.

Dosage in the marketing authorisation

2.2 The recommended dose is 125 mg, taken orally, once daily for 21 consecutive days, followed by 7 days off treatment (28-day cycle). Treatment should be continued as long as the patient is having clinical benefit from therapy or until unacceptable toxicity happens.


2.3 The cost is £2,950 for a 21-capsule pack of 125 mg capsules (excluding VAT; British national formulary online, accessed October 2019). The company has a commercial arrangement. This makes palbociclib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)